Authors: Van Laethem, K Witvrouw, M Pannecouque, C Van Remoortel, B Schmit, JC Esnouf, R Kleim, JP Balzarini, J Desmyter, J De Clercq, E Vandamme, AM

Citation: K. Van Laethem et al., Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype, AIDS, 15(5), 2001, pp. 553-561

Authors: Hsiou, Y Ding, JP Das, K Clark, AD Boyer, PL Lewi, P Janssen, PAJ Kleim, JP Rosner, M Hughes, SH Arnold, E

Citation: Y. Hsiou et al., The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance, J MOL BIOL, 309(2), 2001, pp. 437-445

Authors: Balzarini, J De Clercq, E Carbonez, A Burt, V Kleim, JP

Citation: J. Balzarini et al., Long-term exposure of HIV type 1-infected cell cultures to combinations ofthe novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors, AIDS RES H, 16(6), 2000, pp. 517-528

Authors: Maguire, M Gartland, M Moore, S Hill, A Tisdale, M Harrigan, R Kleim, JP

Citation: M. Maguire et al., Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virologicalevaluation of the AVANTI 2 and AVANTI 3 studies, AIDS, 14(9), 2000, pp. 1195-1201

Authors: Rakik, A Ait-Khaled, M Griffin, P Thomas, DA Tisdale, M Kleim, JP

Citation: A. Rakik et al., A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors, J ACQ IMM D, 22(2), 1999, pp. 139-145

Authors: Kleim, JP Winters, M Dunkler, A Suarez, JR Riess, G Winkler, I Balzarini, J Oette, D Merigan, TC

Citation: Jp. Kleim et al., Antiviral activity of the human immunodeficiency virus type 1 specific nonnucleoside reverse transcriptase inhibitor HBY097 alone and in combination with zidovudine in a phase II study, J INFEC DIS, 179(3), 1999, pp. 709-713